|
1
|
Zacherl J: The current evidence in support
of multimodal treatment of locally advanced, potentially resectable
esophageal cancer. Dig Dis. 32:171–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: High-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ando N, Iizuka T, Ide H, Ishida K, Shinoda
M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, et al;
Japan Clinical Oncology Group. Surgery plus chemotherapy compared
with surgery alone for localized squamous cell carcinoma of the
thoracic esophagus: A Japan Clinical Oncology Group Study -
JCOG9204. J Clin Oncol. 21:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar
|
|
5
|
Zhu L, Du H, Shi M, Chen Z and Hang J: ATG
deficiency promote apoptotic death induced by Cisplatin in human
esophageal squamous cell carcinoma cells. Bull Cancer. 100:15–21.
2013.PubMed/NCBI
|
|
6
|
Sato Y, Motoyama S, Nanjo H, Ito S,
Yoshino K, Sasaki T, Kuribayashi K, Nagaki Y, Imai K, Saito H, et
al: REG1A expression status suggests chemosensitivity among
advanced thoracic esophageal squamous cell carcinoma patients
treated with esophagectomy followed by adjuvant chemotherapy. Ann
Surg Oncol. 20:3044–3051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo W, Zhao YP, Jiang YG, Wang RW, Hong L
and Fan DM: Upregulation of ZNRD1 enhances cisplatin resistance in
human esophageal cancer cells by regulation of ERCC1 and Bcl-2.
Tumour Biol. 29:188–194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hesketh PJ: Chemotherapy-induced nausea
and vomiting. N Engl J Med. 5: 358:2482–2494. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nooter K, Kok T, Bosman FT, van Wingerden
KE and Stoter G: Expression of the multidrug resistance protein
(MRP) in squamous cell carcinoma of the oesophagus and response to
pre-operative chemotherapy. Eur J Cancer. 34:81–86. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo
KJ, Zhang X, Li YF and Fu JH: Establishment and biological analysis
of the EC109/CDDP multidrug-resistant esophageal squamous cell
carcinoma cell line. Oncol Rep. 22:65–71. 2009.PubMed/NCBI
|
|
11
|
Sakai NS, Samia-Aly E, Barbera M and
Fitzgerald RC: A review of the current understanding and clinical
utility of miRNAs in esophageal cancer. Semin Cancer Biol. 23(6 Pt
B): 512–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kihara C, Tsunoda T, Tanaka T, Yamana H,
Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, et
al: Prediction of sensitivity of esophageal tumors to adjuvant
chemotherapy by cDNA microarray analysis of gene-expression
profiles. Cancer Res. 61:6474–6479. 2001.PubMed/NCBI
|
|
13
|
Shimoji T, Miki Y and Nagasaki K: Gene
expression profiling for prediction of response to chemotherapy.
Gan To Kagaku Ryoho. 33:1–5. 2006.(In Japanese). PubMed/NCBI
|
|
14
|
Chen LI, Stuart L, Ohsumi TK, Burgess S,
Varshney GK, Dastur A, Borowsky M, Benes C, Lacy-Hulbert A and
Schmidt EV: Transposon activation mutagenesis as a screening tool
for identifying resistance to cancer therapeutics. BMC Cancer.
13:932013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Burnight ER, Cooney AL, Malani N,
Brady T, Sander JD, Staber J, Wheelan SJ, Joung JK, McCray PB Jr,
et al: PiggyBac transposase tools for genome engineering. Proc Natl
Acad Sci USA. 110:E2279–E2287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hay RJ, Park J-G and Gazdar A: Atlas of
Human Tumor Cell Lines. Academic Press; pp. 269–282. 1994
|
|
17
|
Nishihira T, Hashimoto Y, Katayama M, Mori
S and Kuroki T: Molecular and cellular features of esophageal
cancer cells. J Cancer Res Clin Oncol. 119:441–449. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ihle JN and Gilliland DG: Jak2: Normal
function and role in hematopoietic disorders. Curr Opin Genet Dev.
17:8–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Levine RL, Wadleigh M, Cools J, Ebert BL,
Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et
al: Activating mutation in the tyrosine kinase JAK2 in polycythemia
vera, essential thrombocythemia, and myeloid metaplasia with
myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sumi K, Tago K, Kasahara T and
Funakoshi-Tago M: Aurora kinase A critically contributes to the
resistance to anti-cancer drug cisplatin in JAK2 V617F
mutant-induced transformed cells. FEBS Lett. 585:1884–1890. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang LS, Chow KC and Wu CW: Expression and
up-regulation of interleukin-6 in oesophageal carcinoma cells by
n-sodium butyrate. Br J Cancer. 80:1617–1622. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suchi K, Fujiwara H, Okamura S, Okamura H,
Umehara S, Todo M, Furutani A, Yoneda M, Shiozaki A, Kubota T, et
al: Overexpression of Interleukin-6 suppresses cisplatin-induced
cytotoxicity in esophageal squamous cell carcinoma cells.
Anticancer Res. 31:67–75. 2011.PubMed/NCBI
|
